Lead Sponsor

Kaken Pharmaceutical

Collaborators

Age

18 - 64 years

Sex

ALL

Healthy Volunteers

No

•Has a clear diagnosis of AD meeting the Hanifin and Rajka criteria for AD that involves both the head/neck and the torso/limbs, and affects 5-30% of the subject's total BSA as determined using the rule of nines
•Has a Baseline IGSS of 3(moderate) or 4(severe) in the selected treatment area on the torso/limbs, and a Baseline IGSS of 2(mild), 3(moderate) or 4(severe) in the selected treatment area on the head/neck.
•Female of childbearing potential has a negative pregnancy test and will be using an effective method of contraception during the study.

•Female who is pregnant, nursing an infant, or planning a pregnancy during the study period.
•Has a Baseline oozing/crusting score of 3(moderate) or greater at the selected treatment area on the head/neck or torso/limbs.
•Presence of a concurrent skin condition that could interfere with assessment of treatment.
•Treatment with any investigational drug or device within 30 days or 5 half lives(whichever is longer) prior to the Baseline visit, or concurrent participation in another clinical trial with an investigational drug or device.